Epidiolex Clinical Review Timeline
Executive Summary
Chronicle of the development and US FDA review of GW Pharmaceutical's Epidiolex (cannabidiol) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients ages 2 and older.
Date |
Action |
IND Chronology (#120,055) |
|
11/14/2013 |
Orphan drug designation granted for the treatment of Dravet syndrome (DS) |
2/11/2014 |
Type B Pre-IND Meeting to discuss clinical pharmacology issues, abuse potential data, and specific trial design concerns |
2/27/2014 |
Orphan drug designation granted for the treatment of Lennox-Gastaut syndrome (LGS) |
3/31/2014 |
IND submitted for a study of the safety and efficacy of cannabidiol in the treatment of convulsive seizures associated with Dravet syndrome |
6/2/2014 |
Fast track designation granted |
6/14/2014 |
Type C meeting (written responses only) to discuss nonclinical requirements, clinical pharmacology issues, abuse potential data, and specific trial design concerns |
12/24/2014 |
Type C meeting (written responses only) to discuss issues regarding clinical pharmacology and abuse potential data |
4/2015 |
GW begins Study 1423 evaluating safety and efficacy of cannabidiol in the treatment of drop seizures in patients with LGS |
6/2015 |
GW begins Study 1414 evaluating safety and efficacy of cannabidiol in the treatment of drop seizures in patients with LGS |
6/24/2015 |
Sponsor proposes proprietary name Epidiolex |
8/12/2015 |
Type C Chemistry, Manufacturing, and Controls (CMC) meeting; Division of Medication Error Prevention and Analysis (DMEPA) raised concerns with sponsor's risk assessment and the proposed 1 mL and 5 mL oral syringes |
10/22/2015 |
Type C meeting (written responses only) to discuss issues of pooled safety and efficacy analyses for two expected DS studies and two expected LGS studies |
11/10/2015 |
FDA finds proprietary name Epidiolex unacceptable |
2/19/2016 |
GW submits an updated use-related risk analysis and a human factors validation study protocol, eliminated 1 mL oral syringe |
4/4/2016 |
GW submits new proposed proprietary name (redacted) |
4/11/2016 |
DMEPA notes deficiencies in review of proposed human factors validation study protocol and provided recommendations to be implemented prior to conducting the human factors validation study |
7/19/2016 |
Type B Pre-NDA Meeting; DNP says it is acceptable for GW to submit Studies 1414 and 1423 concurrently to support an indication for LGS |
9/26/2016 |
FDA finds new proposed proprietary name conditionally acceptable |
4/20/2017 |
Rare pediatric disease designation granted for LGS and DS |
5/2/2017 |
Rolling NDA review request granted |
NDA Chronology (#210,365) |
|
8/4/2017 |
GW submits the results of their human factors validation study as part of their rolling submission |
10/29/2017 |
NDA Submitted |
12/20/2017 |
NDA designated for priority review |
12/20/2017 |
Botanical Review Team (BRT) provides 18 questions to GW |
2/1/2018 |
BRT participates in Office of Pharmaceutical Quality (OPQ)-only teleconferences with GW to ask additional questions pertaining to the quality control of the botanical raw material |
2/20/2018 |
Mid-cycle communication; agency indicates a REMS was not likely to be required |
2/20/2018 |
BRT provides six additional questions to GW |
2/22/2018 |
BRT participates in OPQ-only teleconferences with GW to ask additional questions pertaining to the quality control of the botanical raw material |
2/23/2018 |
GW submits additional information on the management of transaminase elevations during the studies |
3/9/2018 |
GW submits request for reconsideration for Epidiolex proprietary name |
3/18/2018 |
GW submits amendment to the request for reconsideration of proprietary name |
3/21/2018 |
ONDP management determines cannabidiol is not a botanical drug substance and can be best described as a highly-purified drug substance |
4/3/2018 |
Late-cycle communication; agency indicates a REMS was not likely to be required |
4/19/2018 |
DMEPA communicates to the DNP that proprietary name Epidiolex is acceptable |
4/19/2018 |
Peripheral and Central Nervous System Drugs Advisory Committee votes 13-0 in favor of risk/benefit profile |
6/25/2018 |
NDA approved for the treatment of seizures associated with DS and LGS in patients ages 2 and older |
6/27/2018 |
PDUFA Date |